H1-2

Chr 6

H1.2 linker histone, cluster member

Also known as: H1.2, H1C, H1F2, H1s-1, HIST1H1C

Histones are basic nuclear proteins responsible for nucleosome structure of the chromosomal fiber in eukaryotes. Two molecules of each of the four core histones (H2A, H2B, H3, and H4) form an octamer, around which approximately 146 bp of DNA is wrapped in repeating units, called nucleosomes. The linker histone, H1, interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher order structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H1 family. Transcripts from this gene lack polyA tails but instead contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6. [provided by RefSeq, Aug 2015]

145
ClinVar variants
6
Pathogenic / LP
0.03
pLI score
12
Active trials
Clinical SummaryH1-2
Population Constraint (gnomAD)
Low constraint (pLI 0.03) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
6 Pathogenic / Likely Pathogenic· 132 VUS of 145 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.86LOEUF
pLI 0.027
Z-score 0.10
OE 0.93 (0.341.86)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-9.84Z-score
OE missense 3.62 (1.972.00)
405 obs / 111.9 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.93 (0.341.86)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.3.62 (1.972.00)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.4.14
01.21.6
LoF obs/exp: 2 / 2.2Missense obs/exp: 405 / 111.9Syn Z: -16.95

ClinVar Variant Classifications

145 submitted variants in ClinVar

Classification Summary

Pathogenic5
Likely Pathogenic1
VUS132
Likely Benign7
5
Pathogenic
1
Likely Pathogenic
132
VUS
7
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
5
0
5
Likely Pathogenic
0
0
1
0
1
VUS
0
126
6
0
132
Likely Benign
0
5
2
0
7
Benign
0
0
0
0
0
Total0131140145

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

H1-2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Septic Shock

The PvCO2-PaCO2/CaO2-CvO2 Ratio in Septic Shock

RECRUITING
NCT07096284Avicenna Military HospitalStarted 2025-01-05
PvCO2-PaCO2/CaO2-CvO2 ratio
Severe Combined Immunodeficiency (SCID)Leaky SCIDOmenn Syndrome

Natural History Study of SCID Disorders

ENROLLING BY INVITATION
NCT01186913National Institute of Allergy and Infectious Diseases (NIAID)Started 2010-09-02
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

ACTIVE NOT RECRUITING
NCT02834013Phase PHASE2National Cancer Institute (NCI)Started 2017-01-30
Biospecimen CollectionComputed TomographyEchocardiography Test
Acute Coronary SyndromeNursing

Acute Coronary Syndrome and Acupressure

RECRUITING
NCT06300294Phase NAAbant Izzet Baysal UniversityStarted 2024-10-01
acupressure
PainSatisfaction

Effects of Shotblocker and Manual Pressure on Pain and Satisfaction

NOT YET RECRUITING
NCT06947525Phase NANecmettin Erbakan UniversityStarted 2025-04-28
Manual pressureShotblocker
Recurrent Malignant GliomaGlioblastomaAnaplastic Astrocytoma

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

ACTIVE NOT RECRUITING
NCT07448480Blokhin's Russian Cancer Research CenterStarted 2026-02-01
Bevacizumab-Containing RegimensNon-Bevacizumab RegimensBRAF ± MEK Targeted Therapy
Aromatherapy

EFFECTS OF CİTRUS AND CLOVE OİL AROMATHERAPY İN OLDER ADULTS

NOT YET RECRUITING
NCT07368374Phase NAMersin UniversityStarted 2026-02-01
Intervention Group 1Intervention Group 2Placebo Control Group
Intensive Care Pediatric

Corticosteroids Before Extubation in Pediatric Intensive Care Unit

NOT YET RECRUITING
NCT06722118Phase PHASE3Assistance Publique - Hôpitaux de ParisStarted 2025-06-15
Dexamethasone IVPlacebo
Septic ShockTachycardiaMortality During Septic Shock

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

RECRUITING
NCT04748796Phase PHASE3Centre Hospitalier Universitaire, AmiensStarted 2021-02-01
echocardiographyLandiolol
Primary Open-Angle Glaucoma (POAG)

GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma

RECRUITING
NCT06921317Phase PHASE1, PHASE2IVIEW Therapeutics Inc.Started 2025-10
GVB-2001-high doseGVB-2001-low dose
Gaucher Disease, Type 2

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

ACTIVE NOT RECRUITING
NCT04411654Phase PHASE1, PHASE2Prevail TherapeuticsStarted 2021-06-29
LY3884961MethylprednisoloneSirolimus
Cerebral Palsy (CP)SpasticityMotor Learning

Predictors of Motor İmagery Performance in Cerebral Palsy

NOT YET RECRUITING
NCT07002567Abant Izzet Baysal UniversityStarted 2025-07-04
Implicit motor imageryExplicit motor imagery